PHARMAPRIM 200 Research Overview
PHARMAPRIM 200 is a pharmaceutical-grade injectable preparation containing drostanolone enanthate, a modified dihydrotestosterone derivative extensively investigated in androgenic steroid research. This compound represents a long-acting ester formulation designed for controlled-release kinetic studies in laboratory environments. Researchers at Stroid UK Shop examine this preparation for its unique structural characteristics and pharmacokinetic properties compared to shorter-acting variants.
Drostanolone enanthate differs significantly from its propionate counterpart through extended elimination half-life profiles, making it valuable for investigating prolonged androgenic receptor binding dynamics. The compound’s molecular structure features specific methyl group positioning that prevents aromatisation to estrogenic metabolites, providing researchers with opportunities to study non-aromatisable androgen effects in isolation. Scientific teams frequently analyse this preparation alongside other drostanolone research compounds to establish comparative potency profiles.
Analytical Research Applications
Laboratory investigations commonly focus on PHARMAPRIM 200’s tissue-selective androgenic activity patterns and protein synthesis modulation mechanisms. Research protocols examine the compound’s interaction with androgen receptor subtypes across different tissue preparations, particularly in muscle and nervous system cultures. Comparative studies evaluate binding affinity differences between drostanolone enanthate and reference androgens like testosterone or nandrolone derivatives.
Metabolic pathway analysis represents another significant research direction, with scientists investigating hepatic enzyme interactions and cytochrome P450 system effects. The compound serves as a valuable research tool for understanding how structural modifications influence androgenic steroid metabolism and clearance mechanisms. Teams studying steroid pharmacology often integrate this preparation with SARM compounds for receptor selectivity comparisons, while peptide researchers examining growth factors may reference it alongside investigational peptides for comprehensive hormonal pathway studies.
Specification Table
| Parameter | Specification |
|---|---|
| Active Compound | Drostanolone Enanthate |
| Concentration | 200mg/mL |
| Formulation | Injectable Solution |
| Manufacturer | Pharmacom Labs |
| Storage Conditions | Room Temperature, Dark, Dry |
| Purity Grade | Pharmaceutical Standard |
| Research Applications | Androgenic Receptor Studies |
| Chemical Class | Modified DHT Derivative |
Laboratory Compliance Notice
PHARMAPRIM 200 is supplied exclusively for qualified research institutions and licensed laboratories conducting in-vitro androgenic steroid investigations. This product is not intended for human consumption, therapeutic application, or any purpose outside controlled scientific research environments. Researchers must maintain appropriate safety protocols, documentation standards, and regulatory compliance throughout all investigational procedures involving this compound.
